Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
GSK and Medicago are now closer to debuting the world's first plant-based COVID-19 vaccine after the completion of phase 3 clinical trial for the efficacy and safety of the immunization that they are developing.
This week, GlaxoSmithKline and Medicago announced getting positive results for their plant-based vaccine candidate for coronavirus. The product is Canadian-made, and it was found to be 71% effective after going through the third level of tests.
According to Canada's CTV News, Medicago Inc., the biotech company headquartered in Quebec, said their Phase 3 placebo-controlled study for their COVID-19 vaccine was conducted in over 24,000 subjects based in six countries.
The participants were 18 years old and older, and the outcome revealed the 71% effectiveness against all variants of coronavirus that were active at the time of the trial. The company further said that they did not find any serious safety issues as well.
The positive results were forwarded to regulators already so it can be authorized to release the world's very first plant-based COVID-19 vaccine worldwide. Just like the other available vaccines today, Medicago and GSK's candidate is also a two-dose injection.
Then again, while the biotech firm said its new vaccine was tested to be effective against the Delta variant but the trial did not include the Omicron variant because it was not yet circulating when the study began.
Currently, the vaccine producer is now processing documents and requirements for filing with health regulators in the U.K., U.S., and other nations. They will also forward the necessary data to World Health Organisation (WHO).
"This is an incredible moment for Medicago and for novel vaccine platforms. The results of our clinical trials show the power of plant-based vaccine manufacturing technology," Medicago chief executive officer and president Takashi Nagao said in a press release. "If approved, we will be contributing to the world's fight against the COVID-19 pandemic with the world's first plant-based vaccine for use in humans."
Finally, Nagao also expressed his gratitude to everyone who took part in the clinical trials, including its partners at GSK, Mitsubishi Tanabe Pharma Corporation, and the government of Canada and Quebec. He did not forget to thank Medicago's workers and shareholders, who are also committed to work on advancing vaccine science at a time when the world needs it.
